Table 4 Quantification of inhibition of mycolate containing products by GSK3011724A.

Inhibitor	Inhibitor concentration (μM)	FAMEs		α-MAMEs		k-MAMEs		TDM		TMM
		c.p.m.	% Relative to control	c.p.m.	% Relative to control	c.p.m.	% Relative to control	c.p.m.	% Relative to control	c.p.m.	% Relative to control
Control	0	9,796	100	4,029	100	7,641	100	3,149	100	1,425	100
GSK3011724A	0.25	16,207	165	3,438	85	7,147	94	ND	ND	ND	ND
	0.5	17,780	182	3,026	75	6,651	87	864	27	911	64
	1	16,478	168	2,488	62	4,925	64	874	28	893	63
	2	18,268	186	1,806	45	4,407	58	ND	ND	ND	ND
	4	ND	ND	ND	ND	ND	ND	652	21	951	67
Control	0	10,231	100	4,156	100	6,722	100	—*	—*	—*	—*
TLM	95	15,334	150	2,721	65	3,727	55	817	26	704	49
INH	1.5	16,926	165	1,426	34	1,808	27	642	20	552	39

α-MAMEs, α-mycolate acid methyl esters; FAMEs, fatty acid methyl esters; INH, isoniazid; k-MAMEs, keto-mycolic acid methyl esters; ND, not determined; TDM, trehalose dimycolate; TLM, thiolactomycin; TMM, trehalose monomycolate.
Quantification of [¹⁴C]-labelled products were determined by excising spots directly from TLC plates (Fig. 2a, left and middle panels, and Fig. 2b) and subjecting them to scintillation counting using 10 ml of EcoScintA.
^*Control values as reported above.

Quick links

Search